This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Emerging Trends in the Management of Hepatitis C Virus Infection: Best Practices for Achieving Sustained Virologic Responses

Emerging Trends in the Management of Hepatitis C Virus Infection: Best Practices for Achieving Sustained Virologic Responses


Slide Lecture Series

Time to Complete

1.50 hours


May 25, 2018


May 25, 2019
Add to Queue

Maximum Credits

1.50 / AMA PRA Category 1 CreditsTM

Pharmacy Credits

Pharmacists may earn 1.50 CPE Credits (0.15 CEUs) by completing this course on the American Society of Health-System Pharmacists (ASHP) website. Please click here to go to the course (you will leave the myCME website, and free registration on the ASHP website is required). Your certificate will save on and will not be included in your myCME CME History.

Accredited Provider

This continuing medical education activity is provided by the American Society of Health-System Pharmacists (ASHP).

Commercial Supporter

Supported by an educational grant from Merck

Program Description

This program will apply emerging evidence and current practice guidelines to address the contemporary challenges in achieving sustained virologic responses (SVR) in all patients with hepatitis C virus (HCV), including those who are difficult to treat. Case studies demonstrating new approaches to managing treatment naive and direct acting antiviral (DAA) experienced patients with resistant HCV infection will be discussed. The program will emphasize the importance of collaboration among healthcare professionals in order to achieve optimal patient outcomes.

Intended Audience

This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of patients with hepatitis C virus infection.

Educational Objectives

At the conclusion of this application-based educational activity, participants should be able to:

  • Discuss trends in the epidemiology of HCV infection and the corresponding recommendations for screening and diagnosis.
  • Apply study data and recommendations from current guidelines for managing treatment naive HCV infected patients, including those who are harder to treat.
  • Evaluate current and emerging treatment options for patients who have had DAA treatment failure.

Conflict Of Interest Disclosure Policy

In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships. In this activity, only the individuals below have disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.


Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP, Activity Chair
Associate Professor, Department of Pharmacy Practice
Jefferson College of Pharmacy
Clinical Pharmacy Specialist, HIV Ambulatory Care
Jefferson Infectious Diseases Associates
Thomas Jefferson University
Philadelphia, PA

Dr. Schafer has nothing to disclose.

William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Dr. Short discloses the following:
Gilead Sciences: Consultant
Janssen Pharmaceuticals: Speaker Bureau

Accredited Provider Disclosure

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.


In order to receive credit, participants must complete the post-test and program evaluation. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue